Sleep and Airway Medicine - An Important Breakthrough in Vivos Therapeutics, Inc.
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
An Important Breakthrough in Sleep and Airway Medicine Vivos Therapeutics, Inc. January 2021 ©2020 Vivos Therapeutics, Inc. ALL RIGHTS RESERVED. CONFIDENTIAL | NOT FOR REDISTRIBUTION
Cautionary Note on Forward-Looking Statements and Disclaimers
This presentation includes statements that constitute “forward-looking statements” within the meaning of the U.S. federal securities laws. These statements relate to
future events or to our future performance, and involve significant known and unknown risks, uncertainties and other factors that may cause our actual results, levels
of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in
these forward-looking statements. These statements include, but are not limited to, information or assumptions about our ability to formulate, implement and gain
market acceptance of our business plan and our products and services, the viability of our intellectual property, our financing needs and plans, and our
management’s plans, goals and objectives for future operations and growth. In some cases, you can identify forward-looking statements by the use of words such as
“may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “continue,” or the negative of these terms or other comparable
terminology. You should not place undue reliance on forward-looking statement since they involve significant known and unknown risks, uncertainties and other
factors which are, in some cases, beyond our control and which could cause actual performance or results to differ materially from those expressed in or suggested
by forward-looking statements.
Important factors that could cause such differences include, but are not limited to: (i) risks and uncertainties associated with the development and implementation of
our VIP Program; (ii) our dependence on key members of our management team; (iii) the risk that we may be unable raise capital when needed; (iv) risks associated
with the timing of, and our ability to achieve, predictable revenue growth and ultimately profitability, if at all; (v) the risk that we may be unable to gain market
acceptance for the Vivos System; and (vi) risks associated with maintaining or protecting the validity of patents and other intellectual property. Should one or more of
these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material or even significant respects from those
projected in these forward-looking statements. We do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as may be required under applicable securities laws. Sales, revenue and other economic estimates have been
determined on-the-basis-of market research and comparable product analysis, but no assurances can be given that such results will be achieved, if at all.
This presentation contains trademarks, trade names and service marks of other companies, which are the property of their respective owners. We do not intend to
use or display of other parties’ trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or
endorsement or sponsorship of us by, these other parties. All references herein to the “Company,” “we,” “us,” “our” and similar terminology refer to Vivos
Therapeutics, Inc.
©2020 Vivos Therapeutics, Inc. ALL RIGHTS RESERVED. CONFIDENTIAL | NOT FOR REDISTRIBUTION 2
Who Are We?
We are a revenue stage medical technology company focused on the
development and commercialization of a highly differentiated
technology offering a clinically effective non-surgical, non-invasive,
non-pharmaceutical, and low-cost alternative for patients with sleep
disordered breathing (SDB), including mild to moderate obstructive
sleep apnea (OSA).
3
©2020 Vivos Therapeutics, Inc. ALL RIGHTS RESERVED. CONFIDENTIAL | NOT FOR REDISTRIBUTION
Strong Market Opportunity for a Potentially Permanent Solution to OSA
Published study by international panel of leading researchers,
reported that nearly one billion people worldwide have sleep apnea.
Obstructive Sleep Apnea
Sleep Apnea Affects nearly 1 Billion
People Worldwide 1
Number of adults suffering from obstructive
Approximately 54 Million people in the sleep apnea in the United States is estimated
U.S. with OSA 2 to be 54 million
Costs Associated with OSA in United
The Vivos System protocol is estimated to be
States in 2016 = $149.6 Billion 3 effective in approximately 80% of cases of
obstructive sleep apnea
U.S. and Canadian addressable market for
Vivos is approximately 43 million adults
U.S. and Canadian Vivos® Market is approximately $69 Billion
1. Healio.com; OSA may affect nearly 1 billion adults worldwide/ www. Healio.com 2. American Academy of Dental Sleep Medicine/ www.aadsm.org 3. Frost & Sullivan; Hidden Health Crisis Costing America Billions
©2020 Vivos Therapeutics, Inc. ALL RIGHTS RESERVED. CONFIDENTIAL | NOT FOR REDISTRIBUTION 4
2020
Corporate Timeline and Milestones
• Stanford University IRB approved clinical trial
for Vivos mRNA appliance in adults aged 21-
63
• 2nd WIRB approved pediatric clinical trial for
guides ages 6-18
• Surpassed 1,200 total Vivos-trained dentists
Submitted the DNA appliance 510k for Class
II clearance device to treat mild-to-moderate
OSA, snoring and SDB in adults; currently
2009-2020 2018 under review by CDRH
2004-2020 • The mmRNA, a modification of the mRNA
• 7 US patents, 2 Canadian patents • Established bricks and mortar appliance, has completed mechanical testing.
• Dr. Singh published “Spatial and 10 registered trademarks retail clinics in Colorado and Utah • Surpassed 15,000 total cases treated with
Matrix Hypothesis” and other • Published approx. 55 articles and featuring The Vivos System the Vivos System
related articles to our studies in professional and peer- • Revenue = $3.8M • Initial Public Offering – NASDAQ: VVOS
technology reviewed journals
2021
• Launch AirO2 Practice
Management Software
• Surpassed 18,000 total
2007-2008 2014 2019 cases treated with the
Vivos System
• Formation of BioModeling • Received FDA 510k approval for
Solutions, an Oregon LLC mRNA appliance ® as a Class II • FDA admin review by CDRH for 510k for DNA appliance underway
• DNA appliance ® registered as device to treat mild-to-moderate • Launched Billing Intelligence Service for medical billing services
Class I device with FDA OSA, snoring and SDB in adults • EU European Patent issued and validated in 10 EU countries
(expires 2029)
• Revenue = $11.4M
• 1st WIRB approved pediatric clinical trial for DNA appliance in
patients aged 7-19
©2020 Vivos Therapeutics, Inc. ALL RIGHTS RESERVED. CONFIDENTIAL | NOT FOR REDISTRIBUTION 5
OSA is a Chronic Disease that Affects over 1 Billion People Globally
Unobstructed Airway
Normal effortless breathing Apnea-Hypopnea Index (AHI) measures sleep apnea severity. The AHI is the sum of the
through the nasal passages during sleep
number of apneas (pauses in breathing) plus the number of hypopneas (periods of shallow
breathing) that occur, on average, each hour. Apneas must last at least 10 seconds to
count as an event.
Obstructive Sleep Apnea
Obstructed Airway
Craniofacial underdevelopment impacts breathing
during sleep by causing an obstruction of the
upper airway
©2020 Vivos Therapeutics, Inc. ALL RIGHTS RESERVED. CONFIDENTIAL | NOT FOR REDISTRIBUTION 6
OSA: A Medical Condition with a Dental Resolution
October 2017
The Role of Dentistry in the
Treatment of Sleep Related
Breathing Disorders
House of Delegates adopts
official policy statement at Dentists are encouraged to screen
ADA 2017 America’s Dental
Meeting patients for Sleep Related Breathing
Disorders.
©2020 Vivos Therapeutics, Inc. ALL RIGHTS RESERVED. CONFIDENTIAL | NOT FOR REDISTRIBUTION
7
The Vivos System – How It Works
The Vivos System has been specifically designed to promote the proper growth and
development of the hard and soft tissues surrounding and comprising the oral cavity,
nasal cavity, upper and lower jaws, and other tissues which together form and shape
the upper airway.
In up to 98% of patients with
OSA, the condition is due to
abnormal anatomical features As these areas develop more fully using the Vivos System, a patient’s airway
typically widens and expands, enabling them to breathe properly through their
of the soft tissues and/or the
nose.
structures of the
maxillomandibular skeleton
that cause a disproportionate With a more open and less obstructed airway, and easier nocturnal breathing, the
anatomy of the airway symptoms of SDB tend to diminish over time, and patients often report they no
longer suffer from the adverse effects of SDB or OSA.
Use of the Vivos System is variable and case dependent, but typically
recommended to be worn daily for 12 to 16 hours starting in the early evening
and continuing overnight. The total treatment time typically ranges from 12 to
Oropharyngeal Examination to Predict Sleep
Apnea Severity: Xavier Barcelo, MD; Rosa M. 24 months with 18 months being the approximate mean treatment time.
Mirapeix, MD, PhD; Jordi Buges, MD; et al: October
2011: Arch Otolaryngol head Neck Surg. 2011;
137(10):990-996. doi: 10.001/archoto.2011.176
©2020 Vivos Therapeutics, Inc. ALL RIGHTS RESERVED. CONFIDENTIAL | NOT FOR REDISTRIBUTION 8
The Vivos System
Biomimetic Oral Appliance Published studies have shown that
Three-Way
expanding the palate and enhancing the
airway using our customized appliances has
3D Axial Springs Development Screws
led to lower AHI scores and a reduction in
OSA
Labial Bow
Vivos DNA Appliance®
The Vivos DNA appliance shown is an FDA registered product.
The mRNA appliance is FDA cleared as a Class II appliance.
The mRNA appliance is cleared to treat mild to moderate sleep apnea, snoring and sleep disordered breathing in adults. Vivos mRNA Appliance®
©2020 Vivos Therapeutics, Inc. ALL RIGHTS RESERVED. CONFIDENTIAL | NOT FOR REDISTRIBUTION 9
The first non-surgical, non-invasive and cost-effective alternative
The Vivos System Offers Significant Benefits
• Average treatment is approximately 18 months for most cases
• Comfortable and easy to wear and to comply with treatment protocols
Nasal Obstruction
• Adults covered by most major medical insurance plans up to 70%
• No known material side effects
• Treatment effective (for its FDA cleared uses)
• Reduce or possibly eliminate the need for surgery or lifetime CPAP or
mandibular advancement therapy
• Improved facial aesthetics (stronger jawline, reduce or eliminate
“gummy” smiles) Appliance in mouth
• Near term benefits from treatment (no waiting for months to see
improvements) Obstructed Airway
©2020 Vivos Therapeutics, Inc. ALL RIGHTS RESERVED. CONFIDENTIAL | NOT FOR REDISTRIBUTION 10Objective Measures Cone-beam Computed Tomography Scans (Before and After) of
Patient – (without an appliance in the mouth)
30-Year-Old Male
14 Months Treatment
BEFORE AFTER
31.4mm2 Min Area: 111.6mm2
13.2cc Total Volume: 26.5cc
After (May 2018)
Before (March 2017)
Min Area: Minimum Cross-sectional Area of Airway
Total Volume: Total Volume of Airway as measured on the scans
©2020 Vivos Therapeutics, Inc. ALL RIGHTS RESERVED. CONFIDENTIAL | NOT FOR REDISTRIBUTION
11Vivos System has shown to lower AHI scores
17 Published studies have shown
98.6%
Reported High
Reduction in AHI that the patented and proprietary
AHI Reduction Score
technologies and protocols
incorporated into The Vivos®
17 Published System alter the size, shape and
Studies Report 67.42%
Reported Mean
Lower AHI AHI Reduction
Reduction in AHI
Score position of the tissues that
scores comprise the human airway,
leading to lower mean AHI scores
38% Reported Low by 67.42% in patients with varying
Reduction in AHI
AHI Reduction
Score degrees of OSA.
Over 18,000 patients treated
©2020 Vivos Therapeutics, Inc. ALL RIGHTS RESERVED. CONFIDENTIAL | NOT FOR REDISTRIBUTION 12Competitive Landscape
Non-Surgical Treatment Options (Non-Invasive) Surgical Treatment Options (Invasive)
Oral Appliance Uvulopalatopharygoplasty Maxillomandibular
Treatment Protocol CPAP Inspire Medical®
Therapy (UPPP Surgery) Advancement Surgery
Target the Underlying Condition YES NO NO NO YES YES
Required Treatment Time to
Potentially Immediate Potentially Immediate Potentially Immediate Potentially Immediate Potentially Immediate Potentially Immediate
Resolve Symptoms
HIGH HIGH HIGH HIGH
Overall Efficacy of Treatment Low/Medium HIGH
(High Patient Compliance) (Low Patient Compliance) (Good Patient Compliance) (With Proper Patient Selection)
Pain Associated with Treatment Minor or None Minor/None Minor/None In Some Cases During Recovery During Recovery
Potential Negative Side-Effects Minor Moderate Moderate Major Major Major
Duration of Treatment/
12-24 Months Lifetime Lifetime Lifetime Surgery + Healing Time Surgery + Healing Time
Intervention
Limited Duration in Potentially Lifetime
Duration of Benefits Potentially Lifetime Only During Use Only During Use Only During Use
Most Cases
Potential Cosmetic Benefits YES YES NO NO NO YES
Health Insurance Coverage YES Yes YES YES YES YES
In Most Cases In Most Cases In Most Cases
$2,500
Est. Average Treatment Cost $9,000 $3,000 - $8,000 $30,000-$40,000 $2,000 - $10,000 $70,000
Plus Consumables
©2020 Vivos Therapeutics, Inc. ALL RIGHTS RESERVED. CONFIDENTIAL | NOT FOR REDISTRIBUTION
13Vivos® Commercial Insurance Reimbursement
CODING PAYMENT COVERAGE
LEVEL OF MANY MAJOR US
CPT CODE E0486
REIMBURSEMENT COMMERICAL MEDICAL
OTHER CPT CODES
BASED ON INDIVIDUAL PAYORS
BASED ON CASE
POLICY
Commercial health Insurance
• Percentage of claims paid depends on several factors,
including: Cost of treatment from individual provider;
Patient’s Medical Policy; Medical Payer’s Guidelines
• Medical insurance is never a guarantee of payment, and
patient deductibles may vary by policy
©2020 Vivos Therapeutics, Inc. ALL RIGHTS RESERVED. CONFIDENTIAL | NOT FOR REDISTRIBUTION 14Our Revenue and Financial Model
Recurring Product Revenue
Revenue per adult case averages $1,600/case
Revenue per pediatric case averages $400/case
One-time Service
Revenue
Enrollment and training fees Recurring Support
for new VIPs * averages Services
$28,000/VIP
Subscription Fees for
Medical Billing &
Advanced Training
* A VIP is a trained dentist – Vivos Integrated Practice
©2020 Vivos Therapeutics, Inc. ALL RIGHTS RESERVED. CONFIDENTIAL | NOT FOR REDISTRIBUTION 15Recurring Product Revenue
Adult Vivos Case $1,600*
Average Adult Case Fee paid to Vivos by Dentist
+70%
GROSS MARGIN
Pediatric Vivos Case $400*
Average Pediatric Case Fee paid to Vivos by Dentist
*Based on Full Pricing and not taking into account promotions or discounts| NOT FOR REDISTRIBUTION
©2020 Vivos Therapeutics, Inc. ALL RIGHTS RESERVED. CONFIDENTIAL | NOT FOR REDISTRIBUTION 16The Economics for a General Dentist
Dentists have hundreds of existing patients of all Illustrative Economics of an Individual Dentist
ages who are suffering from OSA
Number of Active Patients in Potential Patients with OSA Potential Additional Revenue
• Typical VIP Dentist has well over 400 existing patients Typical Dental Practice for Dentist
who may suffer from (undiagnosed) OSA
• Represents a multi-million-dollar revenue opportunity for 1,250 375 $3,375,000
dental practices
1,500 450 $4,050,000
$9,000
Typical Case Fee to Patient 1,750 525 $4,725,000
($3,000) 2,000 600 $5,400,000
Estimated Total Cost to DDS
$6,000 2,250 675 $6,075,000
Estimated Total Margin DDS
©2020 Vivos Therapeutics, Inc. ALL RIGHTS RESERVED. CONFIDENTIAL | NOT FOR REDISTRIBUTION
17Vivos® Patient Process Flow
How Patients Learn about The Treatment Plan and
The Diagnostic Process Manufacturing Appliance
Vivos®
©2020 Vivos Therapeutics, Inc. ALL RIGHTS RESERVED. CONFIDENTIAL | NOT FOR REDISTRIBUTION 18Our Competitive Strengths
• FDA registrations and clearances since 2009
• Significant barriers to entry
• Vivos System Insurance reimbursement
• Body of published research and strong patient outcomes
• First mover advantage
• Differentiated products
• Intellectual property portfolio and research and development capabilities
• Extensive Training and Support Systems
• Compelling economics and value-added services to VIPs at all levels of the product and service delivery chain
• Marketplace acceptance – over 18,000 patients treated – over 1,200 Dentists trained
©2020 Vivos Therapeutics, Inc. ALL RIGHTS RESERVED. CONFIDENTIAL | NOT FOR REDISTRIBUTION 19Our Sales and Marketing Strategy
• Expand our North American (U.S. and Canada) sales and marketing organization to drive adoption of our Vivos System and
other products and services. We believe that a strong sales and support team to train dentists and other ancillary
healthcare providers on the use and the benefits of Vivos System will increase sales.
• Drive medical and dental community awareness of Vivos System. Through our recently established Medical Integration
Division we are seeking strategic alliances within the medical and dental communities to increase awareness of our product
• Increase indirect marketing channels. We have been successful through strategic alliances within the medical and dental
communities to increase awareness of our products
• Build patient awareness of the Vivos System. We plan to continue building patient awareness through our direct-to-patient
marketing initiatives.
• Invest in research and development to drive innovation and expand indications. We are committed to ongoing research and
development.
• Expand into international markets. We have trained dentists from many different countries all over the world.
©2020 Vivos Therapeutics, Inc. ALL RIGHTS RESERVED. CONFIDENTIAL | NOT FOR REDISTRIBUTION 20VIP Vivos Sales Organization Primary salesperson
A Vivos Sales Team is made up of FIVE components • Responsible for enrolling new
Enrollment
VIPs
Specialist
Onboarding Specialists Enrollment Support Staff
• Responsible for onboarding Onboarding Support Staff
Specialists • Responsible for organizing
new VIPs to our training Members potential VIP appointments
programs for Enrollment Specialists
Outreach and Engagement Associates Business Development Associates
• Responsible for engaging with potential • Responsible for cultivating new
Outreach & Business
VIPs in our sales process with surveys business leads which are referred to
and offers of online courses with the Engagement Development
the Enrollment Support Staff
purpose of leads to be referred to the
Enrollment Support Staff members
©2020 Vivos Therapeutics, Inc. ALL RIGHTS RESERVED. CONFIDENTIAL | NOT FOR REDISTRIBUTION 21Vivos Integrated Healthcare Network Growth Over1,200 Clinicians Trained
When a Dentist enrolls as a Vivos Integrated Practice (VIP),
they are placed into a localized support system that includes:
• Integrated Clinical Advisor
Clinical Advisors are experienced
practicing dentists who provide
advisory and mentorship
• Integrated Market Advisor
Market Advisors assist in the
planning and enrollment
process
• Integrated Practice Advisor
Practice Advisors assist in the
integration and
implementation process
Individual network cells provide
regional and local support for
Vivos® Integrated Practices
©2020 Vivos Therapeutics, Inc. ALL RIGHTS RESERVED. CONFIDENTIAL | NOT FOR REDISTRIBUTION 22Summary Unaudited Financial Data
Summary historical consolidated financial data as Nine months ended September 30, Year ended December 31,
Select Financial Data 2019 2020 2018 2019
of and for the nine months ended September 30,
Condensed Statement of Operations
2020 and 2019 and years ended December 31,
Revenue
2019 and 2018. Audited 2019 and 2018 financial
Product revenue 2,833,895 3,513,216 24% 1,848,375 4,349,623 135%
statements are available upon request. Service revenue 5,503,648 6,246,081 13% 1,943,886 7,043,654 262%
Total revenue 8,337,543 9,759,297 17% 3,792,261 11,393,277 200%
Cost of sales (1,871,001) (2,034,486) 9% (1,081,641) (2,736,034) 153%
Gross profit 6,466,542 7,724,811 19% 2,710,620 8,657,243 219%
Gross margin 78% 79% 1 pp 71% 76% 5pp
Operating expenses and interest (14,515,431) (13,517,078) -7% (11,046,802) (19,234,476) 74%
Interest income/expense/other (78,442) (15,140) -81% (102,974) (177,086) 72%
Net loss (8,127,331) (5,807,407) -29% (8,439,156) (10,754,319) 27%
Net loss per common share, basic and fully diluted $ (0.72) $ (0.52) -28% $ (0.82) $ (0.95) 16%
Condensed Balance Sheet Data 12/31/19 9/30/20 12/31/18 12/31/19
Cash and cash equivalents 469,353 1,550,129 230% 1,254,723 469,353 -63%
Current assets 1,984,155 3,385,037 71% 2,011,596 1,984,155 -1%
Total assets 7,551,537 8,484,121 12% 8,203,967 7,551,537 -8%
Current liabilities 9,093,683 6,996,095 -23% 2,157,157 9,093,683 322%
Total liabilities 9,177,929 8,493,796 -7% 2,710,507 9,177,929 239%
Total liabilities and stockholders equity 7,551,537 8,484,121 12% 8,203,967 7,551,537 -8%
©2020 Vivos Therapeutics, Inc. ALL RIGHTS RESERVED. CONFIDENTIAL | NOT FOR REDISTRIBUTION 23Vivos Leadership Team
R. Kirk Huntsman is a co-founder of our company and has served as our Chief Executive Officer and a director since September 2016. In June 2020, he was elected Chairman of the
Board by our board of directors. In 1995, he founded Dental One (now Dental One Partners), which, as President and Chief Executive Officer he grew to become one of the leading
DSOs (dental service organizations) in the country, with over 165 practices in 15 states. After a successful sale of Dental One to MSD Capital in 2008 and subsequent merger in 2009
with Dental Care Partners, Mr. Huntsman was appointed in 2010 as Chief Executive Officer of ReachOut Healthcare America, a Morgan Stanley Private Equity portfolio company. In
2012, he founded Xenith Practices, LLC, a DSO focused on rolling up larger independent general dental offices, which was sold in 2015. From January 2014 to September 2015, Mr.
Huntsman founded and served as the Chief Executive Officer of Ortho Ventures, LLC, a US distributor of certain pediatric oral appliances with applications for pediatric sleep
disordered breathing. Since November 2015, he has served as the Chief Executive Officer of First Vivos, Inc., which is now our wholly owned subsidiary. He was also a founding member
of the Dental Group Practice Association (DGPA), now known as the Association of Dental Support Organizations (ADSO). He is the father of Todd Huntsman. He holds a BS degree in
finance from Brigham Young University.
G. Dave Singh, DMD, Ph.D., DDSc. Is the founder of our company and has served as our Chief Medical Officer and as a director since September 2016. Until June 2019, he also
served as our President. Since January 2008, Dr. Singh served as the Chief Executive Officer of BioModeling Solutions, Inc., which became our wholly owned subsidiary. Dr. Singh is
regarded as a leading professor in the field of SDB in all its many forms. He was awarded a grant by the British Society for Developmental Biology (University of Oxford, UK), and later
was appointed to the Board of Examiners, Royal College of Surgeons of England. As an “outstanding professor” supported by Harvard University, University of Michigan, and University
of Hawaii, he was invited to relocate to the US where he led a NIH-funded program of clinical craniofacial research. Currently, he is a Board Member of the American Sleep and Breathing
Association and Member of the World Sleep Society. He has published over 200 articles in the peer-reviewed medical, dental and orthodontic literature, and 7 books/chapters. His
pioneering research into epigenetic influencers on craniofacial growth and development led to the development of the patented DNA appliance® and mRNA appliance® technology. He
holds a DDSc in orthodontics from University of Dundee, UK, a Ph.D. in Craniofacial Development from University of Bristol, UK, and a BDS/DMD in dentistry from University of
Newcastle, UK. In 2020, Dr. Singh was given a lifetime achievement award as one of the world’s top 100 doctors in dentistry for his work on sleep apnea.
Bradford Amman has served as our Chief Financial Officer of since October 2018. From January 2017 to October 2018, Mr. Amman served as the Chief Financial Officer and Chief
Operations Officer of InLight Medical, a manufacturer and distributor of medical devices cleared by the FDA for increased circulation and reduced pain. Prior to InLight, from 2010 to
2017, he served as CereScan Corp.’s Chief Financial Officer. CereScan specializes in state-of-the-art functional brain imaging, utilizing a patented process, the latest generation
functional imaging SPECT and PET cameras and the industry’s leading brain imaging software to assist in the diagnosis of a magnitude of brain-related conditions and disorders. Mr.
Amman served as Chief Financial Officer of LifeVantage Corporation from 2006 to 2010, including during its initial public offering. Mr. Amman holds a Masters of Business
Administration from the University of Notre Dame and a BS in Accounting from the University of Denver.
©2020 Vivos Therapeutics, Inc. ALL RIGHTS RESERVED. CONFIDENTIAL | NOT FOR REDISTRIBUTION 24Vivos Board of Directors
Ralph E. Green, DDS, MBA Anja Krammer
Ralph joined our board in June 2020. He has devoted more than 35 years to senior level Anja joined our board in June 2020. In early 2020, Ms. Krammer was appointed as the Chief
executive positions. Since 2003, Dr. Green has served as President and CEO of his proprietary Executive Officer of Turn Biotechnologies, a development stage company focused on reversing aging
dental practice. From 2003 to 2017 he served as Vice President of Clinical Affairs for ReachOut and age-related diseases. From 2013 through 2018, she co-founded, served as President, Secretary
Healthcare America, a Morgan Stanley Private Equity company focused on Arizona’s underserved and a director of BioPharmX, a specialty pharmaceutical company where she led the initial public
children’s population. From1997 through 2002, Dr. Green was President of Zila Pharmaceuticals offering onto the New York Stock Exchange in 2015. Ms. Krammer served as Principal/Founder of MBI,
Inc. where he was engaged in clinical trials, patent development and regulatory approval Inc., a management consulting firm beginning in January 1998. While at MBI, Inc., Ms. Krammer also
submissions. Dr. Green has done extensive research on bone growth and oral cancer. In the mid- served as Vice President Global Marketing from April 2006 to August 2008 for Reliant Technologies, a
1980’s, Bofors Nobel-Pharma, selected Dr. Green to establish the Swedish Branemark Dental venture-backed startup in aesthetic medicine. From April 2004 to April 2006, Ms. Krammer served as
Implant in America, now known as Nobel Biocare, the global leader in dental implants with several Sr. Director of Strategic Marketing for Medtronic Corporation. From December 2000 to September
billions in sales. In 1987, Dr. Green discovered and patented a method of activating the titanium 2001, Ms. Krammer was Vice President, Solutions Marketing for Getronics Corporation, a global IT
implant surface to enhance its success rate. He started his own titanium implant company, OTC services company. From April 1999 to December 2000, Ms. Krammer served as Vice President, Indirect
America, which was acquired after 18 months by Collagen Corporation, where he served as Senior Channel Sales and Worldwide Industry Partnership Marketing in the Itronix Division of Acterna
Vice President. Following his tenure at Collagen, he started his own consulting firm, Biofusion Corporation, an optical communications company. Ms. Krammer’s other prior roles include serving as
Technology. Director of Worldwide Marketing and Communications for Tektronix Corporation in its Color Printing
and Imaging Division from October 1997 to April 1999.
He also served as Assistant Professor in the Tufts University School of Medicine and
School of Dental Medicine in the 1970’s and 1980’s. Dr. Green has served as President-elect and From October 1995 to October 1997, Ms. Krammer was Director of Worldwide Sales and
director of the Dental Manufacturers of America. He was honored as a fellow in the Academy of Marketing with KeyTronic Corporation, a computer equipment manufacturer. Ms. Krammer holds a BAIS
International Dentistry in Nice, France. Dr. Green holds a DDS from the University of Iowa, an MBA degree with a focus on Marketing/Management from the University of South Carolina and an
from Boston University and a BA in Biology from Graceland University. International Trade Certificate from the University of Paris—Sorbonne.
©2020 Vivos Therapeutics, Inc. ALL RIGHTS RESERVED. CONFIDENTIAL | NOT FOR REDISTRIBUTION
25Vivos Board of Directors
Mark F. Lindsay Leonard J. Sokolow
Mark joined our board in June 2020. Since 2008, he has served as a consultant and the Leonard joined our board in June 2020. Since 2015, Mr. Sokolow has been Chief Executive
director of the healthcare and pharmaceuticals practices group with the Livingston Group, From Officer and President of Newbridge Financial, Inc., a financial services holding company and Chairman of
February 2001 through September 2008, Mr. Lindsay was with UnitedHealth Group, one of the Newbridge Securities Corporation, its full service broker-dealer. From 2008 through 2012, he served as
world’s largest healthcare companies, where he held a number of senior positions including President of National Holdings Corporation, a publicly traded financial services company. From
President of the AARP Pharmacy Services Division and Vice President of Public Communications November 1999 until January 2008, Mr. Sokolow was Chief Executive Officer and President, and a
and Strategy. In 2008, he served on President Obama’s transition team. From May 1996 through member of the Board of Directors, of vFinance Inc., a publicly traded financial services company, which
January 2001, Mr. Lindsay served in President Clinton’s White House as Assistant to the President he cofounded. Mr. Sokolow was the Chairman of the Board of Directors and Chief Executive Officer of
for the Office of Management and Administration. His areas of responsibility included the White vFinance Inc. from January 2007 until July 2008, when it merged into National Holdings Corporation, a
House Military Office, which managed Air Force One; The White House Communications Agency; publicly traded financial services company. Mr. Sokolow was founder, chairman and chief executive
the Medical Unit and Camp David; running the White House Operations; and the Executive Office of officer of the Americas Growth Fund Inc., a closed-end 1940 Act management investment company,
the President’s Office of Administration, which was responsible for finance, information systems, from 1994 to 1998. From 1988 until 1993, Mr. Sokolow was an Executive Vice President and the
human resources, legal/appropriations and security. Mr. Lindsay’s office was responsible for the General Counsel of Applica Inc., a publicly traded appliance marketing and distribution company.
logistics of all domestic and international Presidential travel and special air missions. President
Clinton selected Mr. Lindsay to be the operational lead for the White House’s 2001 transition From 1982 until 1988, Mr. Sokolow practiced corporate, securities and tax law and was one of
preparation and execution. From 1994 through 1997, Mr. Lindsay served as senior legislative aid the founding attorneys and a partner of an international boutique law firm. From 1980 until 1982, he
and counsel to Congressman Louis Stokes (D-OH). He worked closely with Democrats and the worked as a Certified Public Accountant for Ernst & Young and KPMG Peat Marwick. Since June 2006,
Congressional Black Caucus on a number of business and economic issues. Mr. Sokolow has served on the Board of Directors of Consolidated Water Company Ltd. (NASDAQ:
CWCO) and as Chairman of its Audit Committee; as well as a member of its Nominations and Corporate
He was also a member of Senator Hillary Clinton’s Minnesota Finance Committee for her Governance Committee since 2011. Since January 2016 Mr. Sokolow has served as a member of the
2008 Presidential campaign. Mr. Lindsay holds a graduate degree from Macalester College in St. Board of Directors of SQL Technologies Corp., d/b/a Sky Technologies and Chairman of its Audit
Paul, Minnesota; a Juris Doctorate from Case Western Reserve University School of Law; a Committee and, since September 2016, Chairman of its Corporate Development Committee, and from
master’s degree in international Affairs from Georgetown University; and a graduate degree from November 2018 through April 30, 2020, he had served as a Board Member and the Independent
the Advanced Management program at the University of Pennsylvania’s Wharton Business School. Manager of Masterworks.io, LLC and its affiliates.
He is a member of the District of Columbia Bar.
©2020 Vivos Therapeutics, Inc. ALL RIGHTS RESERVED. CONFIDENTIAL | NOT FOR REDISTRIBUTION 26Vivos Board of Directors
Matthew Thompson, M.D.
Matthew joined our board in June 2020. Since December 2016, Dr. Thompson has served as Chief
Medical Officer of Endologix LLC. Dr. Thompson is an Adjunctive Professor at Stanford School of
Medicine (since 2017) and contract surgeon and Visiting Professor Cleveland Clinic Lerner
College of Medicine of Case Western Reserve University (since 2020). Prior to joining Endologix,
Dr. Thompson served as Professor of Vascular Surgery at St. George’s University of London and
St George’s Vascular Institute (2002-2016). Dr. Thompson’s awards include a Hunterian
Professorship, the Moynihan traveling fellowship and the gold medal for the intercollegiate
examination. Dr. Thompson is also the editor of the Oxford Textbook of Vascular Surgery and the
Oxford Handbook of Vascular Surgery. Dr. Thompson was Chair of the National Specialized
Commissioning Clinical Reference Group (2013-2016) for Vascular Services and is a founder of
the British Society for Endovascular Therapy (2004). Dr. Thompson was a Council Member of the
Vascular Society (2014-2017), Chairman of the Vascular Society Annual Scientific Meeting (2014-
2017). Dr Thompson was the clinical director for three London-wide service reconfigurations
(cardiovascular disease, major trauma and emergency services) (2010-2013). Dr. Thompson
trained at Cambridge University (1981-1984), St. Bartholomew’s Hospital (1984-1987), the
University of Leicester (1994) and Adelaide (1998).
©2020 Vivos Therapeutics, Inc. ALL RIGHTS RESERVED. CONFIDENTIAL | NOT FOR REDISTRIBUTION 27Vivos Leadership Team
Susie McCullough is a co-founder of our company and has served as the Senior Vice President – Operations of our company since September 2016. Since November 2015, she has also
served as the Sr. VP – Operations of First Vivos, Inc., which is a wholly owned subsidiary of Vivos Therapeutics, Inc. From January 2015 to October 2015 Ms. McCullough was a Vice
President for Perfect Start. From February 2009 to December 2014, Ms. McCullough was the Director of Practice Development for Dental One Partners and was responsible for revenue
generation for 165 dental offices located across the United States. Ms. McCullough has over 30 years of experience in the dental industry. From August 1998 to May 2002 she attended The
Hubbard College of Business Administration and received her Consulting License.
D. Bryan Ferre has served as our Senior Vice President – Marketing since September 2017. From June 2011 until September 2015, Mr. Ferre had served as Chief Executive Officer/founder
of Bryan Ferre Creative International Partners, a private branding and marketing company. From May 2008 to December 2010, he served as Chief Executive Officer of Zipadi, where he
designed and developed a mobile application rapid development environment and a platform-as-a-service. From 2013 to February 2008, he served as Chief Marketing Officer of Firstline
Wave. Mr. Ferre holds a BA in Graphic Design.
Cathryn H. Bonar has served as Senior Vice President – Compliance & Medical Billing of our company since November 2017.. From July 2014 until August 2017, Ms. Bonar had served as
Owner and Director of Reimbursity Medical Billing Services, Inc., which created and implemented a medical billing process and protocol for billing medical insurance for Dentists and Oral
Surgeons across the country. From 2010 to 2014, she had served as a partner and director of Medical EZ Billing. Ms. Bonar is regarded as an expert in medical billing for the dental practice
and has been featured in various professional periodicals for her work. She has also lectured at various dental conventions, across the country, on medical billing for continuing education.
Mrs. Bonar has initiated and developed company compliance procedures, quality record management and regulatory processes. She initiated and leads our Compliance Committee to
ensure and execute company compliance with the laws and governing regulatory bodies applicable to Vivos Therapeutics. She has become an invaluable resource to Vivos Therapeutics
procuring FDA clearances and clinical trials throughout the country. Ms. Bonar holds a Bachelor of Science from Liberty University, Lynchburg, VA.
Edward Loew has served as Senior Vice President of Strategy of our company since October 2017. From April 2011 to January 2016, he served as President and CEO of Veebo, Inc., a
national mobile marketing company. From January 2011 to February 2012, he served as Chief Investment Officer of Amerifunds Diversified Funding, LLC, where he refined organization
structure to consolidate, streamline and delineate necessary functions. From March 2002 to December 2007 Mr. Loew served as Director of Lending of a public reporting real estate
investment company and lender based in Scottsdale, Arizona. During his tenure, he helped originate, fund and manage a portfolio of approximately $1.2 billion in real estate and real estate
loans. Mr. Loew has been featured in USA Today and Popular Science Radio. Mr. Loew is an invaluable resource to strategy and new business development by recognizing both physical and
organization structure to increase efficiency and drive productivity to new levels. Mr. Loew brings senior-level program implementation and strategic skills relative to multi-tiered operational
environments. Mr. Loew holds a BA in Political Science from Arizona State University.
©2020 Vivos Therapeutics, Inc. ALL RIGHTS RESERVED. CONFIDENTIAL | NOT FOR REDISTRIBUTION 28You can also read
